Literature DB >> 10903781

Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups.

L Mollet1, T S Li, A Samri, C Tournay, R Tubiana, V Calvez, P Debré, C Katlama, B Autran.   

Abstract

The influence of HIV burden variations on the frequencies of Ag-specific CD8+ T cell responses was evaluated before and during highly active antiretroviral therapy by analyzing the number, diversity, and function of these cells. The frequencies of HLA-A2-restricted CD8+ PBL binding HLA-A2/HIV-epitope tetramers or producing IFN-gamma were below 1%. A panel of 16 CTL epitopes covering 15 HLA class I molecules in 14 patients allowed us to test 3.8 epitopes/patient and to detect 2.2 +/- 1.8 HIV epitope-specific CD8+ subsets per patient with a median frequency of 0.24% (0.11-4. 79%). During the first month of treatment, viral load rapidly decreased and frequencies of HIV-specific CD8 PBL tripled, eight new HIV specificities appeared of 11 undetectable at entry, while CMV-specific CD8+ PBL also appeared. With efficient HIV load control, all HIV specificities decayed involving a reduction of the CD8+CD27+CD11ahigh HIV-specific effector subset. Virus rebounds triggered by scheduled drug interruptions or transient therapeutic failures induced four patterns of epitope-specific CD8+ lymphocyte dynamics, i.e., peaks or disappearance of preexisting specificities, emergence of new specificities, or lack of changes. The HIV load rebounds mobilized both effector/memory HIV- and CMV-specific CD8+ lymphocytes. Therefore, frequencies of virus-specific CD8 T cells appear to be positively correlated to HIV production in most cases during highly active antiretroviral therapy, but an inverse correlation can also be observed with rapid virus changes that might involve redistribution, sequestration, or expansion of these Ag-specific CD8 T cells. Future strategies of therapeutic interruptions should take into account these various HIV-specific cell dynamics during HIV rebounds.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903781     DOI: 10.4049/jimmunol.165.3.1692

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy.

Authors:  Michael P Weekes; Mark R Wills; J G Patrick Sissons; Andrew J Carmichael
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

4.  Early establishment and antigen dependence of simian immunodeficiency virus-specific CD8+ T-cell defects.

Authors:  Yvonne M Mueller; Constantinos Petrovas; Duc H Do; Susan R Altork; Tracy Fischer-Smith; Jay Rappaport; John D Altman; Mark G Lewis; Peter D Katsikis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

5.  Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire.

Authors:  Dirk Meyer-Olson; Kristen W Brady; Melissa T Bartman; Kristin M O'Sullivan; Brenna C Simons; Joseph A Conrad; Coley B Duncan; Shelly Lorey; Atif Siddique; Rika Draenert; Marylyn Addo; Marcus Altfeld; Eric Rosenberg; Todd M Allen; Bruce D Walker; Spyros A Kalams
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

6.  Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection.

Authors:  Heather A Prentice; Hailin Lu; Matthew A Price; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Susan Allen; Paul A Goepfert; Eric Hunter; Jill Gilmour; Jianming Tang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

7.  HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Authors:  Aude G Chapuis; Corey Casper; Steve Kuntz; Jia Zhu; Annelie Tjernlund; Kurt Diem; Cameron J Turtle; Melinda L Cigal; Roxanne Velez; Stanley Riddell; Lawrence Corey; Philip D Greenberg
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

8.  High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys.

Authors:  David H Margolin; Erika F Helmuth Saunders; Benjamin Bronfin; Nicole de Rosa; Michael K Axthelm; Xavier Alvarez; Norman L Letvin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.

Authors:  Kellie N Smith; Robbie B Mailliard; Charles R Rinaldo
Journal:  For Immunopathol Dis Therap       Date:  2015

10.  Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.

Authors:  J P Casazza; M R Betts; L J Picker; R A Koup
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.